At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 4 enrolled
Drug / intervention
Ixekizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Ixekizumab in the Treatment of Bullous Pemphigoid
In Brief
A Phase 2 clinical trial evaluating Ixekizumab for Bullous Pemphigoid and Pemphigoid. Completed, enrolled 4 participants across 1 site.
Detailed Summary
Recently, Interleukin (IL)-17 has been identified as a key driver of chronic inflammation in Bullous Pemphigoid (BP). Ixekizumab is a recombinant high-affinity fully human monoclonal antibody that targets IL-17A Immunoglobulin gamma-1 (IgG1)/kappa-class. The purpose of this study is to determine the effect of Ixekizumab on BP patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBullous Pemphigoid, Pemphigoid
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartAug 2017
Primary CompletionJun 2019
TodayJul 2026
First PostedApr 4, 2017
Enrollment StartAug 15, 2017
Primary CompletionJun 6, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.2 years ago
Interventions
Ixekizumabdrug
Subcutaneous injection